Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review
Open Access
- 22 September 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (10), 3070
- https://doi.org/10.3390/jcm9103070
Abstract
In the present study, we aimed to report our experience with rituximab (RTX) in the treatment of patients with ILD associated with AD (AD-ILD) at a single center. For this purpose, clinical characteristics, radiological findings, and pulmonary function tests (PFTs) of RTX-treated AD-ILD-patients seen from May 2016 until March 2020 at a referral center for individuals with ILD were retrospectively reviewed. Additionally, an updated literature review was conducted. A total of 26 patients (mean age 58.3 ± 11.1 years at ILD diagnosis) was included. The most common ADs related to ILD were systemic sclerosis, idiopathic inflammatory myositis (including anti-synthetase syndrome) and rheumatoid arthritis. Non-specific interstitial pneumonia (n = 12) and usual interstitial pneumonia (n = 11) were the predominant radiological patterns. The sustained improvement in PFTs was observed from the start of RTX, with a statistically significant increase in DLCO from basal to one year after RTX (mean + 4.2%, p = 0.024). Overall, there were no differences when comparing PFT outcome according to the radiological pattern or the specific type of AD. In conclusion, RTX constitutes a good therapeutic option to preserve lung function in patients with AD-ILD, regardless of the radiological pattern or the underlying AD.This publication has 85 references indexed in Scilit:
- The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung diseaseRespiratory Medicine, 2013
- Clinical aspects of autoimmune rheumatic diseasesThe Lancet, 2013
- Effective Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease by B-Cell Targeted Therapy with RituximabCase Reports in Immunology, 2012
- Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroidsTherapeutic Advances in Respiratory Disease, 2011
- Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failureMultidisciplinary Respiratory Medicine, 2011
- Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle studyRheumatology, 2009
- Rituximab treatment of the anti-synthetase syndrome—a retrospective case seriesRheumatology, 2009
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2009
- Effects of rituximab on resistant SLE disease including lung involvementLupus, 2009
- Dermatomiositis refractaria asociada a neumonía en organización tratada con rituximab: Reporte de un casoRevista médica de Chile, 2009